TCR2 Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. No pricing details were mentioned in the filing, although the offering was valued up to $100 million, but this is normally just a placeholder. The company intends to list its shares on the Nasdaq under the symbol TCRR.
The underwriters for the offering are Jefferies, Leerink Partners, BMO Capital Markets, Wedbush PacGrow and China Renaissance.
This is an innovative immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. Its proprietary TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex, which the firm believes is essential for T cell therapies to be effective in patients with solid tumors.
The company also has designed its TRuC-T cells so that tumor cell recognition does not require human leukocyte antigens (HLA), which provides two important additional benefits. First, in contrast to current engineered T cell therapies that use the full TCR, this technology is designed so that it can be applied to all patients that express the cancer surface antigen irrespective of HLA subtype, which the firm believes will allow it to address a significantly larger patient population. Second, HLA is downregulated or lost in many tumors, which can prevent their recognition by T cells and lead to diminished response rates and higher relapse rates.
As a result, management believes this approach will allow the firm to deliver the first HLA-independent TCR-T cell therapy for patients with solid tumors. It also believes that the product candidates have the potential to improve upon the efficacy and safety of currently approved chimeric antigen receptor T (CAR-T) cell therapies in CD19-positive B-cell hematological malignancies. This belief is based on preclinical studies comparing product candidates to CAR-T cells that the firm has engineered.
The company intends to use the net proceeds from this offering to further its pipeline, as well as for working capital and general corporate purposes.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
